212 related articles for article (PubMed ID: 31524157)
1. Intraneuronal Tau Misfolding Induced by Extracellular Amyloid-β Oligomers.
Rudenko LK; Wallrabe H; Periasamy A; Siller KH; Svindrych Z; Seward ME; Best MN; Bloom GS
J Alzheimers Dis; 2019; 71(4):1125-1138. PubMed ID: 31524157
[TBL] [Abstract][Full Text] [Related]
2. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
3. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
[TBL] [Abstract][Full Text] [Related]
4. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer disease: a tale of two prions.
Nussbaum JM; Seward ME; Bloom GS
Prion; 2013; 7(1):14-9. PubMed ID: 22965142
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
Bloom GS
JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
[TBL] [Abstract][Full Text] [Related]
7. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
8. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
9. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
[TBL] [Abstract][Full Text] [Related]
10. Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.
Crestini A; Santilli F; Martellucci S; Carbone E; Sorice M; Piscopo P; Mattei V
J Alzheimers Dis; 2022; 85(2):503-518. PubMed ID: 34864675
[TBL] [Abstract][Full Text] [Related]
11. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
[TBL] [Abstract][Full Text] [Related]
12. The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation.
Amar F; Sherman MA; Rush T; Larson M; Boyle G; Chang L; Götz J; Buisson A; Lesné SE
Sci Signal; 2017 May; 10(478):. PubMed ID: 28487416
[TBL] [Abstract][Full Text] [Related]
13. The dark side of Alzheimer's disease: unstructured biology of proteins from the amyloid cascade signaling pathway.
Gadhave K; Gehi BR; Kumar P; Xue B; Uversky VN; Giri R
Cell Mol Life Sci; 2020 Oct; 77(20):4163-4208. PubMed ID: 31894361
[TBL] [Abstract][Full Text] [Related]
14. Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.
Winton MJ; Lee EB; Sun E; Wong MM; Leight S; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2011 May; 31(21):7691-9. PubMed ID: 21613482
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-β oligomers in cellular models of Alzheimer's disease.
Fontana IC; Zimmer AR; Rocha AS; Gosmann G; Souza DO; Lourenco MV; Ferreira ST; Zimmer ER
J Neurochem; 2020 Nov; 155(4):348-369. PubMed ID: 32320074
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons.
Ramser EM; Gan KJ; Decker H; Fan EY; Suzuki MM; Ferreira ST; Silverman MA
Mol Biol Cell; 2013 Aug; 24(16):2494-505. PubMed ID: 23783030
[TBL] [Abstract][Full Text] [Related]
17. Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer's Disease.
Mroczko B; Groblewska M; Litman-Zawadzka A; Kornhuber J; Lewczuk P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954063
[TBL] [Abstract][Full Text] [Related]
18. The Toxicity and Polymorphism of β-Amyloid Oligomers.
Huang YR; Liu RT
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599696
[TBL] [Abstract][Full Text] [Related]
19. The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer's Disease (AD).
Mroczko B; Groblewska M; Litman-Zawadzka A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547024
[TBL] [Abstract][Full Text] [Related]
20. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
